continued rebound: trends in life science m&a
DESCRIPTION
TRANSCRIPT
![Page 1: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/1.jpg)
Continued Rebound:Trends in Life Science M&ATrends in Life Science M&ASilicon Valley BankJuly 2012
Written By: yJonathan NorrisManaging [email protected]
1
![Page 2: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/2.jpg)
Agenda • Part I:Overview of 2011 Big ExitsAgenda Part I:Overview of 2011 Big Exits• Part II: Analysis by Indication
o Series A Investment by Indication between 2005 and 2011
o LPI and Hit Rate – Measuring Indication Performance in the Life Science Industry
2
![Page 3: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/3.jpg)
Overview of Big ExitsOverview of Big Exits
3
![Page 4: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/4.jpg)
M&A Big Exits Per Year (2005-2011)g ( )
4
![Page 5: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/5.jpg)
Total Big Exit Dollar Volumeg
5
![Page 6: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/6.jpg)
Average Time to Exitg
6
![Page 7: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/7.jpg)
Biotech Deal Typeyp
7
![Page 8: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/8.jpg)
Biotech Big Exitsg
8
![Page 9: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/9.jpg)
Biotech Structured Deal Breakdown
9
![Page 10: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/10.jpg)
Biotech Breakdown by Stage, Round, Years to Exity g , ,
10
![Page 11: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/11.jpg)
Biotech Upfront Payments by Stage in Structured Deal Era (2009-2011)( )
11
![Page 12: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/12.jpg)
Device Big Exitsg
12
![Page 13: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/13.jpg)
Device Structured Deal Breakdown
13
![Page 14: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/14.jpg)
Device Stage Breakdowng
14
![Page 15: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/15.jpg)
Device Capital Efficient Exits by Multiplep y p
15
![Page 16: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/16.jpg)
Analysis By Indicationy y
16
![Page 17: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/17.jpg)
Life Science Series A Data
17
![Page 18: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/18.jpg)
Biotech Series A Data
18
![Page 19: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/19.jpg)
Device Series A Data
19
![Page 20: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/20.jpg)
Life Science Investments by Indicationy
20
![Page 21: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/21.jpg)
Indication Breakdown: Biotech
21
![Page 22: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/22.jpg)
Indication Breakdown: Med Device
22
![Page 23: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/23.jpg)
Biotech Indication Performance Data
23
![Page 24: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/24.jpg)
Device Indication Performance Data
24
![Page 25: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/25.jpg)
Disclosures
This material, including without limitation the statistical information herein, is provided for informational purposes only The material is based in part upon information from third-partyinformational purposes only. The material is based in part upon information from third-party sources that we believe to be reliable, but which has not been independently verified by us and, as such, we do not represent that the information is accurate or complete. The information should not be viewed as tax, investment, legal or other advice nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific
f i l d i b f ki i t t d i i N thi l ti t th t i lprofessional advice before making any investment decision. Nothing relating to the material should be construed as a solicitation or offer, or recommendation, to acquire or dispose of any investment or to engage in any other transaction.
U.S. VC-backed Service companies were included under the device category. Services t d l th 10 t f ll d l i thi t R ti l f i l direpresented less than 10 percent of all deals in this category. Rational for including
Services was to try and capture as much U.S. LS Venture investment as possible -creating an additional category with a small data set did not make sense.
©2012 SVB Financial Group All rights reserved Member Federal Reserve System©2012 SVB Financial Group. All rights reserved. Member Federal Reserve System. SVB>, SVB>Find a way, SVB Financial Group, and Silicon Valley Bank are registered trademarks. B-12-12265. Rev. 07-16-12.
25
![Page 26: Continued Rebound: Trends in Life Science M&A](https://reader034.vdocuments.us/reader034/viewer/2022051818/54c13fe44a795991518b4631/html5/thumbnails/26.jpg)